Aurora Diagnostics, a leading independent pathology services and cancer diagnostics company, today announced the acquisition of CytoPath, bringing to 30 the number of affiliated local pathology practices around the country.
Based just south of Birmingham in Alabaster, Ala., CytoPath is a physician-owned medical practice providing surgical pathology and cytopathology services to eight hospitals and five referring physician group clients in Central and Southern Alabama.
"We are very pleased to welcome the highly regarded CytoPath team to our growing family of pathology practices," said Daniel D. Crowley, President, Chairman and CEO of Aurora Diagnostics. "Their history of supporting local community hospitals and physicians in Alabama makes the CytoPath team an ideal addition to our organization."
"Aurora Diagnostics is well known to us via their excellent Cunningham Pathology practice in Birmingham, and we are very pleased to be part of the same team," said Teresa Venz-Williamson, MD, President of CytoPath. "Aurora's commitment to community-based pathology practices supporting local hospitals and physicians makes it a great cultural fit for us. In addition, Aurora brings resources dedicated to information technology, payor relations, human resources, clinical research, sales and marketing, and purchasing. We look forward to working with a team of committed colleagues and providing many more decades of diagnostic excellence to the hospitals and physicians we serve."
Terms of the transaction were not disclosed.
About Aurora Diagnostics
Aurora Diagnostics is the leading independent anatomic pathology and cancer diagnostics company in the U.S. Its 30 community-based practices, with more than 190 board-certified pathologists, offer integrated diagnostic and personalized medicine consultations to thousands of physicians.
Referring physicians include dermatologists, obstetricians and gynecologists, family practitioners, gastroenterologists, urologists, general surgeons, and oncologists. Aurora pathologists provide diagnostic opinions and work collaboratively with them to determine appropriate patient treatment options.
Aurora Diagnostics is also a leader in hospital lab management services, supporting 140 hospitals throughout the country.
Additionally, the Company's Aurora Research Institute subsidiary is a leader in helping hospitals and independent labs ethically provide tissue and blood samples to researchers on the cutting edge of research for effective cancer treatments.
For additional information regarding Aurora Diagnostics and the services it provides, please visit the company website at www.auroradx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005732/en/
Halldin PR
Bill Halldin, 916-781-0657
bill@halldinpr.com